Last reviewed · How we verify
NCT00873808
Long-Term Bone Quality in Women With Breast Cancer (A Companion Study to S0307)
trial testing clodronate disodium in Breast Cancer. Withdrawn.
1 February 2010
Quick facts
| Lead sponsor | SWOG Cancer Research Network |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 1 October 2008 |
| Primary completion | 1 February 2010 |
| Estimated completion | 1 February 2010 |
| Sites | 1 location across United States |
Drugs / interventions tested
- clodronate disodium
- demeclocycline hydrochloride — full drug profile →
- ibandronate sodium
- tetracycline hydrochloride — full drug profile →
- zoledronic acid (ZOLEDRONIC ACID) — full drug profile →
- laboratory biomarker analysis — full drug profile →
- adjuvant therapy — full drug profile →
- computed tomography
- dual x-ray absorptiometry
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
SWOG Cancer Research Network
Who can join
18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
- Change in bone quality after long-term high-dose bisphosphonates as measured by histomorphometry, mineralization density, micro-computed tomography, and biomechanics of bone biopsy samples
Sponsor's own description
RATIONALE: Gathering information over time from imaging and laboratory tests of women receiving bisphosphonates for breast cancer may help doctors learn more about long-term bone quality and plan the best treatment. Tetracycline hydrochloride and demeclocycline hydrochloride can mark the new growth of the bone, so it may be seen better under a microscope. PURPOSE: This clinical trial is studying long-term bone quality in women with breast cancer enrolled on clinical trial SWOG-S0307.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy.
Williams CB, Yeh ES, Soloff AC. · · 2016 · cited 357× · PMID 26998515 · DOI 10.1038/npjbcancer.2015.25 -
Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer.
Li C, Xu X, Wei S, Jiang P, et al · · 2021 · cited 259× · PMID 33504575 · DOI 10.1136/jitc-2020-001341 -
Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis.
Adams A, Jakob T, Huth A, Monsef I, et al · · 2024 · cited 11× · PMID 38979716 · DOI 10.1002/14651858.cd013451.pub2 -
HDAC Inhibition with Valproate Improves Direct Cytotoxicity of Monocytes against Mesothelioma Tumor Cells.
Hoyos C, Fontaine A, Jacques JR, Heinen V, et al · · 2022 · cited 6× · PMID 35565292 · DOI 10.3390/cancers14092164
Verify or expand the search:
- PubMed search for NCT00873808
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of clodronate disodium
Trials testing the same drug.
- NCT00003232 — Combination Chemotherapy in Treating Pain in Hormone Refractory Metastatic Prostate Cancer · Phase 3 · completed
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other SWOG Cancer Research Network trials
Trials by the same sponsor.
- NCT07498205 — Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts · Phase 4 · not yet recruiting
- NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
- NCT07278739 — Testing an Educational Program to Improve Goals of Care Conversations Between Patients and Their Care Teams · NA · not yet recruiting
- NCT06769126 — Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM · Phase 2 · recruiting
- NCT07018869 — Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colore · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00873808 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by SWOG Cancer Research Network
- Last refreshed: 9 April 2013
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00873808.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing